Table 2.
Recent trials of erlotinib and radiotherapy in NSCLC.
| Trial | Year | Trial type | N | Disease type | Treatment | Efficacy outcome | Safety outcomesa |
|---|---|---|---|---|---|---|---|
| Martinez et al. (2008) | 2008 | Phase II randomized | 23 | Unresectable stage I–IIIA NSCLC | RT (arm 1) vs. RT + erlotinib (arm 2) | RR: arm 1, 55.5%; arm 2, 83.3% | Grade 3 toxicities: arm 1, pneumonitis (4%); arm 2, radiodermatitis (8%) |
| Lind et al. (2009) | 2008 | Phase I single arm | 11 | NSCLC brain metastases | WBRT + concurrent erlotinib | Of 7 patients with follow-up imaging, PRs in 5 and SD in 2 | Grade 3–5 toxicities: interstitial lung disease (18%), acneiform rash (9%), fatigue (9%) |
| von Pawel et al. (2008) | 2008 | Case reports | 2 | NSCLC recurrent brain metastases and parallel thoracic progression | WBRT + sequential erlotinib | Survival >18 and 15 months, respectively | No severe toxicities reported |
NSCLC, non-small cell lung cancer; PR, partial response; RR, response rate; RT, radiotherapy; SD, stable disease; WBRT, whole-brain radiotherapy.
aMost commonly reported moderate-to-severe adverse events.